← Human Trials & Peer-Reviewed Studies
A study of luteal phase expression of inhibin, activin, and follistatin subunits in the endometrium of women with recurrent miscarriage.
Plain-language guide to PMID 17074342 (2006): controlled clinical trial of Follistatin-344 in 10 women, endometriosis.
Key Facts
- PMID
- 17074342
- Journal
- Fertility and sterility
- Year
- 2006
- Study type
- Controlled Clinical Trial
- Authors
- Prakash A et al. (6 authors)
- DOI
- 10.1016/j.fertnstert.2006.05.040
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial looks at Follistatin-344 in the context of endometriosis.
To compare the luteal phase endometrial expression of inhibin, activin, and follistatin subunits in women with recurrent miscarriage compared to a control group.
Other parameters of luteal function assessed included Doppler blood flow, serum biochemical markers, and histopathology.
Who Took Part
The abstract describes 10 women taking part.
By PubMed's age tags, the people studied were adults, women only.
Thirty-three women with recurrent miscarriage and 10 women with no previous history of miscarriage (control group) were recruited.
Histologic assessment of the luteal phase endometrium was done using Noyes criteria followed by immunohistochemical analysis for expression of inhibin, activin, and follistatin subunits.
How the Study Was Run
This was a prospective case control study.
The study was conducted in a tertiary care hospital of Sheffield, United Kingdom.
Doppler analysis for perifollicular and endometrial blood flow was also done.
Simultaneously serum concentrations of E(2), LH, FSH, P, and inhibin B at the time of LH surge and at LH +7 days were measured.
What Was Measured
PubMed files the paper under topics including Abortion, Habitual, Activins, Biomarkers, Case-Control Studies, Endometrium, Follistatin and Inhibins.
What This Means in Plain Language
This is a controlled clinical trial of Follistatin-344 in 10 women in people with endometriosis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2006 (Fertility and sterility), a journal based in United States.
More context: the Follistatin-344 compound page, Endometriosis research.
Our Notes on the Compound
Follistatin-344: A myostatin- and activin-binding protein studied in gene-therapy trials for muscular dystrophy; black-market vials have been found mislabeled.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.